C1P.F CONSUN PHARMAC.GR.HD -10
- Market cap
- EUR 1.48B
- P/E
- 10.4x
- P/B
- 2.35x
- ROE
- 23.8%
- Dividend yield
- 5.01%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is C1P.F undervalued?
Graham numberC1P.F trades 4.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CONSUN PHARMAC.GR.HD -10 fundamental analysis
No fundamental analysis for CONSUN PHARMAC.GR.HD -10 yet.
CONSUN PHARMAC.GR.HD -10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well…
Full company profileCONSUN PHARMAC.GR.HD -10 financial statements
CONSUN PHARMAC.GR.HD -10 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.04B | 2.34B | 2.59B | 2.97B | 3.42B |
| Gross Profit | 1.53B | 1.76B | 1.92B | 2.24B | 2.67B |
| Operating Income | 652M | 719M | 810M | 963M | 1.15B |
| EBITDA | - | 834M | 963M | 1.11B | 1.27B |
| Net Income | 590M | 683M | 785M | 910M | 1.08B |
| EPS | 0.72 | 0.85 | 0.99 | 1.07 | 1.28 |
| Balance Sheet | |||||
| Total Assets | 4.36B | 4.89B | 5.51B | 5.85B | 6.41B |
| Total Liabilities | 1.45B | 1.45B | 1.59B | 1.46B | 1.57B |
| Shareholders' Equity | 2.62B | 3.15B | 3.63B | 4.10B | 4.54B |
| Cash & Short-term Investments | 2.20B | 2.45B | 2.75B | 2.91B | 1.23B |
| Cash Flow | |||||
| Operating Cash Flow | 726M | 948M | 819M | 1.09B | 1.21B |
| Capital Expenditure | 98.3M | 51.6M | 52.6M | 109M | 68.5M |
| Free Cash Flow | 627M | 896M | 766M | 978M | 1.14B |
| Ratios | |||||
| ROE | 22.5% | 21.7% | 21.6% | 22.2% | 23.8% |
| ROA | 13.5% | 14.0% | 14.2% | 15.6% | 16.8% |
| Net Profit Margin | 28.9% | 29.2% | 30.3% | 30.7% | 31.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CONSUN PHARMAC.GR.HD -10 dividends
- Dividend yield
- 5.01%
- Forward dividend
- 0.09 EUR
- Payout ratio
- 46.2%
- Ex-dividend date
- Sep 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 498M | 0.59 | 46.2% |
| 2024 | CNY 681M | 0.80 | 74.7% |
| 2023 | CNY 326M | 0.41 | 41.6% |
| 2022 | CNY 127M | 0.16 | 18.7% |
| 2021 | CNY 198M | 0.24 | 33.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns CONSUN PHARMAC.GR.HD -10
- Insiders 45.67%
- Institutions 24.50%
- Public & others 29.83%
- Shares outstanding 838M
- Free float 456M
CONSUN PHARMAC.GR.HD -10 company profile
- Company name
- CONSUN PHARMAC.GR.HD -10
- Ticker
- C1P.F
- ISIN
- KYG2524A1031
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,847
- Fiscal year end
- December
- Address
- 71, Dongpeng Avenue, Guangzhou, China
- Phone
- 86 20 8226 4529
- Website
- chinaconsun.com
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. In addition, the company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules; and gastroenterology medicines, tonics, and other medicines. Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.
CONSUN PHARMAC.GR.HD -10 management
8- Mr. Meng AnCEO & Executive Chairman · born 1971
- Ms. Yujun ChenChief Financial Officer · born 1980
- Prof. Quan ZhuChief Scientist & Non-Executive Director · born 1940
- Mr. Yuk Chuen YoungExecutive Director · born 1998
- Lei ZhouAssistant President
- Mr. Haien GaoCompany Secretary · born 1969
- Mr. Guorong GuoChairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd
- Ms. Lianhui ChenChairman & GM of Consun Pharmaceutical (Horgos) Co., LTD.